Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells

Author's Avatar
Jun 10, 2021

Company Continues to Advance Technologies Described in its >1000 Claim Patent on Cellular Therapy for Schizophrenia

PR Newswire